Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Jubilant Pharmova's US facility Line 3 gets FDA nod for commercial production

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at pharma.economictimes.indiatimes.com →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

Jubilant Pharmova's Spokane-based US facility received FDA approval for commercial batch manufacturing on its new Line 3, featuring an isolator-based fill and finish line with a capacity of 55 million units annually and advanced sterile injectable technologies.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You can expand your US sterile injectable supply by partnering with a newly FDA-approved CDMO in Spokane, which means faster market access for liquid and lyophilized products.

◆ Coverage

1 source · 24 Aug 2026

◆ Related on Wire

◆ Topics

Medtechfda-approvalcommercial-productionsterile-injectablescdmopharma-manufacturing